Terrence P. Cescon

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial

Susan Montgomery, Andrea M. Barsevick, Brian L. Egleston et al. · Familial Cancer · 2013 · 92 citations

Life Sciences, Genetics, Molecular Genetics +12

Quality of life after pharmacomechanical catheter-directed thrombolysis for proximal deep venous thrombosis

Susan R. Kahn, Jim A. Julian, Clive Kearon et al. · Journal of Vascular Surgery Venous and Lymphatic Disorders · 2019 · 86 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Paclitaxel/Carboplatin/Etoposide Versus Gemcitabine/Irinotecan in the First-Line Treatment of Patients With Carcinoma of Unknown Primary Site

John D. Hainsworth, David R. Spigel, Bobby L. Clark et al. · The Cancer Journal · 2010 · 66 citations

Medicine, Oncology, Pharmacology +11